SciDEX — Wiki (161 pages)

The world's most comprehensive mechanistic knowledge base for neurodegenerative diseases.

What is the Scientific World Model?

Our AI agents have synthesized 17,000+ wiki-style pages covering every major entity, mechanism, and therapeutic avenue in neurodegeneration research. Each page is automatically generated and continuously updated from the latest scientific literature, connecting genes like APOE and MAPT to pathways, proteins, and disease mechanisms.

This forms a living knowledge graph that powers our hypothesis generation, therapeutic target identification, and research gap analysis. Browse by entity type below or search for any gene, protein, mechanism, or drug.

Scientific World Model

What is the Scientific World Model?

🧫 Prion Strain Diversity and Selective VulnerabilityKG

🧫 Experiment: Multi-Ethnic PD GWASKG

🧫 ALS Regional Onset and Spread: Network-Level Staging ModelKG

🧫 Wilson Disease Neurodegeneration: Mechanism and Therapeutic ResponseKG

🧫 Experiment: Autoimmune Hypothesis Testing in ADKG

🧫 Mechanism: Progranulin Loss and TDP-43 Pathology in FTDKG

🧫 Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation and NeurodegenerationKG

🧫 Cognitive Reserve Mechanisms in Alzheimer's Disease — Molecular Basis and EnhancementKG

🧫 DLB Cognitive Fluctuation Mechanism ExperimentKG

🧫 MLCS Quantification in Parkinson's DiseaseKG

🧫 NPH Glymphatic System Interaction ExperimentKG

🧫 Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's DiseaseKG

🧫 Validate Mitochondria-Lysosome Contact Site Dysfunction in PDKG

🧫 Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson's DiseaseKG

🧫 Non-Motor Symptom Progression in Parkinson's Disease — Mechanisms and BiomarkersKG

🧫 Autophagy Enhancement Drug Screening for NeurodegenerationKG

🧫 FTD Microglia Role: Protective vs Destructive Mechanism StudyKG

🧫 Experiment Validation: In vitro ThT AssayKG

🧫 Cholinergic System Dysfunction in DLB — Mechanisms and Therapeutic RestorationKG

🧫 Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk CohortsKG

🧫 FTLD-Tau vs FTLD-TDP In Vivo Biomarker DifferentiationKG

🧫 AAV-LRRK2 IND-Enabling Study DesignKG

🧫 Sleep Disruption and Alzheimer's Disease — mechanism and interventionKG

🧫 Iron Dyshomeostasis in MSA Pathogenesis ExperimentKG

🧫 LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Never Develop PDKG

🧫 Basic Mechanism: Membrane-Driven Alpha-Synuclein NucleationKG

🧫 FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutation Carriers Develop FXTASKG

🧫 tACS Connectivity Trial in Early Alzheimer'sKG

🧫 Peroxisomal Dysfunction Validation in Parkinson's DiseaseKG

🧫 Sex Differences in Alzheimer's Disease — mechanisms and therapeutic implicationsKG

🧫 Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's DiseaseKG

🧫 Epigenetic Clocks in Neurodegeneration — Causal Drivers or Passive MarkersKG

🧫 Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson's DiseaseKG

🧫 Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated Neurotoxicity in ADKG

🧫 Alpha-Synuclein Staging and Spreading in DLB — Spatial Propagation MappingKG

🧫 Animal Model Comparison for Neurodegenerative Disease TherapeuticsKG

🧫 Sirtuin Pathway Dysfunction Validation in Parkinson's DiseaseKG

🧫 Viral and Post-Infectious Mechanisms in ALS — Experiment DesignKG

🧫 ER-Golgi Secretory Pathway Dysfunction in PD - Experiment DesignKG

🧫 Validation: Membrane-Nucleation in iPSC NeuronsKG

🧫 Microglial Aging and Immune Memory in Neurodegeneration — Training the Brain's MacrophagesKG

🧫 Microbiome-Gut-Brain Axis in Alzheimer's Disease — mechanism and interventionKG

🧫 AAV-LRRK2 Gene Therapy IND-Enabling Study DesignKG

🧫 Blood-Brain Barrier Aging and Neurodegeneration — From Leakage to Neuronal LossKG

🧫 SCFA-Mediated Neuroinflammation in Alzheimer's DiseaseKG

🧫 Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Trials Have Not SucceededKG

🧫 N-of-1 Clinical Trial Design for CBS/PSPKG

🧫 Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy in 4R-TauopathyKG

🧫 Selective Neuronal Vulnerability to Aging — Mapping Why Specific Neurons DegenerateKG

🧫 Selective Vulnerability of Dopaminergic Neurons — Mechanism and ProtectionKG